Takeda’s Position on Counterfeit, Falsified and Illegal Trading of Healthcare Products

Background
The purpose of this position statement is to describe Takeda’s mission is to strive towards better health for people worldwide through leading innovation in medicine. In carrying out our mission, we prioritize patients, trust with society, our reputation and our business, in that order.

Counterfeit, falsified and other illegally traded medicines present significant threats to consumers and patients around the globe. With the growing trend of illegal operations targeting medicines used to treat and prevent complex diseases, the industry faces increasing challenges to safeguard patient health and its products.

Takeda is proactively taking a holistic, risk-based approach to identify and mitigate the risk of falsified, illegal, and other types of suspect products to ensure patient safety. A dedicated Global Product Protection team employs a strategic approach, by collaborating with internal functions and external agencies to carry out this mission.

Takeda’s position
The following principles guide Takeda’s approach to counterfeit, falsified and illegal trading of healthcare products:

• We proactively partner with international and local law enforcement, regulatory agencies, other pharmaceutical companies and industry organizations to combat counterfeiting and illegal trading, while also educating patients, supply chain partners and customers on the dangers associated with these activities. Through partnerships, such as IFPMA “Fight the Fakes” Campaign and Alliance for Safe On Line Pharmacies (ASOP), we do contribute to grass roots education to patients.
• We routinely set high security standards and requirements for supply chain partners worldwide, perform due diligence and audit against these requirements.
• We evaluate, develop and implement innovative anti-counterfeiting solutions for products and packaging to deter and detect counterfeiting, theft, diversion and tampering.
• We detect, investigate and collect evidence against entities suspected of engaging in illegal trade of Takeda product on a continuous basis, which includes active monitoring and disruption of illegal online pharmacies and other illicit Internet trading.
Closing

The counterfeiting, falsification and illegal trade of healthcare products is not a problem that Takeda can tackle alone. Takeda strives to form strong partnerships and promote innovation to protect patient safety.

We encourage the industry to do the same through organizations like the Global Alliance for Safe Online Pharmacies, Rx-360 and Pharmaceutical Security Institute, IFPMA, and Asia Pacific Economic Cooperation Life Science Innovation Forum and others.

April 2019